

## Zinc Fingers and Homeoboxes 2 (*Zhx2*) Regulates Sexually Dimorphic *Cyp* Gene Expression in the Adult Mouse Liver

Kate Townsend Creasy,<sup>\*1</sup> Jieyun Jiang,<sup>†</sup> Hui Ren,<sup>†</sup> Martha L. Peterson,<sup>†‡</sup> and Brett T. Spear<sup>†‡</sup>

<sup>\*</sup>Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, USA

<sup>†</sup>Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, KY, USA

<sup>‡</sup>Markey Cancer Center, University of Kentucky, Lexington, KY, USA

The mammalian cytochrome P450 (*Cyp*) gene family encodes a large number of structurally related enzymes that catalyze a variety of metabolic and detoxification reactions. The liver is the primary site of *Cyp* expression in terms of expression levels and number of expressed genes, consistent with this organ's essential role in metabolism of endogenous and xenobiotic compounds. Many *Cyp* genes exhibit sexually dimorphic expression. For example, *Cyp2a4* is expressed significantly higher in the adult liver of female mice compared to male mice. An exception to this pattern is seen in BALB/cJ mice, where male hepatic *Cyp2a4* mRNA levels are substantially elevated compared to male mice of other strains. The Zinc fingers and homeoboxes 2 (*Zhx2*) protein governs the silencing of several genes in the postnatal liver, including  $\alpha$ -fetoprotein, H19, and glypican 3. *Zhx2* also regulates numerous hepatic genes that govern lipid homeostasis. We previously showed that the *Zhx2* gene is mutated in BALB/cJ mice, which led us to consider whether elevated male hepatic *Cyp2a4* levels in this strain are due to this *Zhx2* mutation. Using mice with a conditional *Zhx2* deletion, we show here that the absence of *Zhx2* in hepatocytes results in increased *Cyp2a4* expression in adult male liver. We extend this finding to show that additional *Cyp* genes are dysregulated in the absence of *Zhx2*. We also show that mRNA levels of *Cyp2a4* and several other female-biased *Cyp* genes are increased, and male-biased *Cyp4a12* is decreased in mouse liver tumors. These data indicate that *Zhx2* is a novel regulator of sex-biased *Cyp* gene expression in the normal and diseased liver.

**Key words: Transcription; Development; Hepatocyte; Regeneration; Knockout mice; Cancer**

### INTRODUCTION

The cytochrome P450 (*Cyp*) supergene family is one of the largest and most diverse gene families in eukaryotes<sup>1,2</sup>. *Cyp* genes encode structurally related enzymes that catalyze a variety of metabolic reactions, including metabolism of steroid-based hormones, lipids, drugs, and environmental chemicals<sup>3</sup>. In humans, mutations in *CYP* genes contribute a variety of metabolic diseases<sup>4</sup>, and polymorphisms in *CYP* genes are a major contributor to variations in susceptibility to xenobiotics<sup>5,6</sup>. The *Cyp* supergene family arose through numerous duplication events<sup>7</sup>. In vertebrates, the number of *Cyp* genes and pseudogenes varies dramatically between different species. Analysis of genome databases suggests that humans contain 57 functional *CYP* genes and 58 *CYP* pseudogenes, whereas mice contain 102 functional *Cyp* genes and 88 *Cyp* pseudogenes<sup>7</sup>.

*Cyp* genes exhibit a variety of expression patterns. Some *Cyp* genes are expressed in multiple tissues, whereas others are more highly restricted to one or several tissues<sup>8–10</sup>. The liver has the highest level of *Cyp* expression, which is not surprising considering the liver's important role in metabolism and because ingested xenobiotics enter the liver before circulation elsewhere in the body. Numerous drugs and xenobiotics can induce *Cyp* gene expression, and much of this is governed by members of the nuclear receptor family, including the constitutive androstane receptor, aryl hydrocarbon receptor, pregnane X receptor, and peroxisome proliferator activated receptor  $\alpha$ <sup>11</sup>. As with structural polymorphisms in *Cyp* enzymes, variation in *Cyp* enzyme expression and induction in response to xenobiotics can lead to different responses to these agents. These variations must be considered when comparing the metabolism and toxicity

<sup>1</sup>Current address: Cardiovascular Research Institute, University of California, San Francisco, 555 Mission Bay Boulevard South, Room 282T, San Francisco, CA 94158, USA.

Address correspondence to Brett T. Spear, Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky College of Medicine, 800 Rose Street, Lexington, KY 40536, USA. Tel: (859) 257-5167; Fax: (859) 257-8994; E-mail: bspear@uky.edu

of drugs and environmental chemicals between different individuals as well as between different species such as mice and humans<sup>12</sup>.

A common feature of many vertebrate *Cyp* genes is sexually dimorphic expression<sup>13</sup>. Many *Cyp* genes are expressed primarily in males, whereas numerous other *Cyp* genes show a female-biased pattern of expression<sup>9</sup>. The degree of sex-biased expression varies considerably. Sex differences in circulating growth hormone (GH) levels play an important role in this sexually dimorphic expression<sup>14</sup>. In the liver, the transcription factors STAT5a/b, hepatocyte nuclear factor 4 $\alpha$  (HNF4 $\alpha$ ), Bcl6, and Cux2 also contribute to sex-biased expression<sup>15-19</sup>.

A dramatic example of sexually dimorphic expression is seen with the murine *Cyp2a4* gene. In normal adult mice, *Cyp2a4* is expressed abundantly in female livers with very low hepatic expression in adult males<sup>20</sup>. Curiously, *Cyp2a4* expression in adult male BALB/cJ mice is substantially increased<sup>21</sup>. Elevated *Cyp2a4* mRNA levels in BALB/cJ males is an autosomal recessive trait. It was speculated that a mutation in a transcriptional repressor resulted in derepression of *Cyp2a4* in adult BALB/cJ male liver<sup>21</sup>.

Several years ago, we identified zinc fingers and homeoboxes 2 (*Zhx2*) as a regulator of gene expression in the postnatal liver. Several *Zhx2* target genes, including  $\alpha$ -fetoprotein (*AFP*), *H19*, and glypican 3 (*Gpc3*) are expressed abundantly in the fetal liver and dramatically repressed in the first several weeks after birth<sup>22,23</sup>. In contrast to other strains of mice, *AFP*, *H19*, and *Gpc3* continue to be expressed in the adult liver of BALB/cJ mice<sup>22-24</sup>. The continued expression of these genes in adult BALB/cJ liver, where *AFP* mRNA levels are 10- to 20-fold higher than other mouse strains, is an autosomal recessive trait regulated by a locus on chromosome 15<sup>25</sup>. Using positional cloning, we found that elevated *AFP*, *H19*, and *Gpc3* mRNA levels in BALB/cJ livers were due to a hypomorphic mutation in the *Zhx2* gene that dramatically reduces *Zhx2* levels<sup>23,26</sup>. Interestingly, when placed on a high-fat diet, BALB/cJ mice have less serum triglycerides and reduced atherosclerotic lesions compared to other mouse strains on the same diet<sup>27</sup>. This strain difference is also due to the *Zhx2* mutation, and several genes involved in lipid/cholesterol homeostasis are dysregulated in BALB/cJ livers<sup>28</sup>. Taken together, these data indicate that *Zhx2* is an important regulator of numerous genes in the postnatal liver.

*Zhx2* is a member of a small gene family that also contains *Zhx1* and *Zhx3*<sup>29</sup>. *Zhx* proteins contain two amino-terminal C<sub>2</sub>-H<sub>2</sub> zinc fingers and four (or five, in the case of *Zhx1*) carboxy-terminal homeodomains<sup>30,31</sup>. In vitro studies suggest that *Zhx* proteins function as transcriptional repressors<sup>29</sup>. This, along with the fact that the *Zhx2* gene is mutated in BALB/cJ mice, led us to investigate whether the mutation in *Zhx2* could account

for elevated *Cyp2a4* expression in adult male BALB/cJ liver. Using a novel mouse model in which *Zhx2* is deleted specifically in hepatocytes, our data indicate that *Cyp2a4* is a target of *Zhx2* repression. Furthermore, we demonstrate that numerous other female-biased *Cyp* genes exhibit increased expression in male livers in the absence of *Zhx2*, although these levels are still considerably lower than what is seen in female liver. We also find that expression of female-biased *Cyp2a4*, *Cyp2b13*, and *Cyp2b9* increases in liver tumors, whereas mRNA levels of male-biased *Cyp4a12* decrease in liver tumors. These data demonstrate that *Zhx2* is an important regulator of sex-specific *Cyp* enzyme expression in the adult liver.

## MATERIALS AND METHODS

### Mice

All mice were housed in the University of Kentucky Division of Laboratory Animal Research (DLAR) facility in accordance with Institutional Animal Care and Use Committee (IACUC)-approved protocols. All mice had ad libitum access to food and water and were maintained on a 12:12-h light/dark cycle.

### Generation of Hepatocyte-Specific *Zhx2* Knockout (*Zhx2* <sup>$\Delta$ hep</sup>) Mice

Breeding pairs of C57BL/6 (BL/6) mice with a floxed *Zhx2* allele (*Zhx2*<sup>fl</sup>) were obtained from the Knock-Out Mouse Project (KOMP) Repository at the University of California–Davis. In these mice, exon 3 has been flanked by *loxP* sites. Since the entire *Zhx2* coding region is found on exon 3, deletion of this exon results in the loss of the entire *Zhx2* protein-coding region. These mice were crossed with BL/6 mice expressing the *Cre* recombinase driven by the liver-specific albumin enhancer/promoter (*Alb-Cre*) (#003574; Jackson Laboratory). Breeding was performed to obtain mice that were homozygous for the floxed *Zhx2* allele with or without the *Alb-Cre* transgene (designated as *Zhx2* <sup>$\Delta$ hep</sup> and *Zhx2*<sup>fl</sup>, respectively). DNA was prepared from tail biopsies obtained when mice were 2 weeks of age, and polymerase chain reaction (PCR) genotyping for the *Zhx2* alleles (wild-type and floxed) and *Alb-Cre* transgene was carried out with ThermoStart Master Mix (Thermo Scientific) as described<sup>32</sup> using primers shown in Table 1. Mice were maintained under normal conditions until they were euthanized at various time points by CO<sub>2</sub> asphyxiation for tissue harvest.

### Developmental Time Point Studies

Female C3H/HeJ (C3H) mice were bred to male BL/6 mice (both strains have wild-type *Zhx2* alleles; The Jackson Laboratory), and female mice were monitored for vaginal plugs to estimate the time of fertilization. For embryonic day 17.5 (e17.5), pregnant females were

**Table 1.** Primer Sequences

Gene	Forward (5')	Reverse (5')
Genotyping		
<i>Cre</i> recombinase	ACCTGAAGATGTTTCGCGATTATCT	ACCGTCAGTACGTGAGATATCTT
<i>Zhx2</i> floxed allele	GGACCGAATCTCACTATTTAACTCA	ACAACGGGTTCTTCTGTTAGTCC
RT-qPCR		
AFP	CCGGAAGCCACCGAGGAGGA	TGGGACAGAGGCCGGAGCAG
CYP1A1	CCGGCATTTCATCCTTCGT	GCCATTCAGACTTGTATCTCTTGTG
CYP1A2	ATCCTTTGTCCCTTCCACAT	GGGAATGTGGGAAGCCATTCA
CYP2A4	GGAAGACGAACGGTGCTTTC	TTC CCA GCA TCA TTC TAA GA
CYP2A5	GGA AGACGAACG GTG CTT TT	TTC CCA GCA TCA TTC GAA GC
CYP2B9	CCTCGACTACATTGCCCATAG	GTTCTGGTGATGGAACCTCTGTG
CYP2B13	GCTTTTCTACCCTTCTCCACAG	ATGTCCTTAGAAGCAACAGGGC
CYP2C40	TGGAAGAGGAAGGATTCCGG	TCACTGTGAAGACCCTTGTGG
CYP2D9	AGAAGTCTCTGGCTTAATTCCTG	GTGGTCCTATCTCAGTCAACAC
CYP2D10	GAAGGTCTTCCAAGGTCAGAAG	CAGCATTCCCCTTACCTTCTC
CYP3A16	GATGCCCTCTTTTTGGTTCTGTTGGC	TCAGGTTGGAATTCTTCAGGCTCTGG
CYP3A25	TCCTTTCACCGAAATCCTGAG	TCCTGGGTCCATTTCCAAAGG
CYP4A10	TCCTTAATGACCCTAGACACTG	TGAAAGATATTCCTCACACGGG
CYP4A12	ATCCTTCTCGATTTGCACCAGG	TTCATCGCAAACGTTCCTCAATG
CYP7A1	GGGCTGTGCTCTGAAGTTCGG	CACAGAGCATCTCCCTGGAGGG
CYP8B1	CAGAGAAAGCGCTGGACTTC	GGCCCCAGTAGGGAGTAGAC
CYP39A1	TGGCTCCTGGCGCTGTTTGGAG	TGGACTGTATTGACGTGTTTCCGTCT
L30	ATGGTGGCCGCAAAGAAGACGAA	CCTCAAAGCTGGACAGTTGTTGGCA
<i>Zhx2</i>	AGGCCGGCCAAGCCTAGACA	TGAGGTGGCCACAGCCACT

ethanized by CO<sub>2</sub> asphyxiation at 17.5 days postconception, and fetuses were removed. For postnatal time points, mice were killed at the designated times after birth. The e17.5 fetuses and postnatal day 7 (p7) mice were euthanized by decapitation; mice at later postnatal time points were euthanized by CO<sub>2</sub> asphyxiation. Livers from mice at all time points were isolated, frozen, and stored at -80°C.

#### *Murine Model of Hepatocellular Carcinoma*

Female C3H mice were bred to male BL/6 mice and monitored until pups were born. At 14 days of age, the male B6C3F1 offspring were injected with either diethylnitrosamine (DEN;  $n = 16$ ; Sigma-Aldrich) or PBS ( $n = 5$ ) at a dose of 10  $\mu$ l/g body weight<sup>33</sup>; these F1 mice were used since they have been shown to be highly susceptible to DEN-induced liver tumors<sup>34</sup>. Mice were weaned at 21 days of age and maintained under normal conditions for 36 weeks, and then euthanized by CO<sub>2</sub> asphyxiation. Livers were removed and examined for hepatocellular carcinoma (HCC) development. Livers from DEN-injected mice had numerous tumors, which were dissected, snap frozen, and stored at -80°C. Livers from age-matched PBS-injected littermates, which were tumor free, were removed, frozen, and stored at -80°C.

#### *RNA Extraction, cDNA Synthesis, and Quantitative Real-Time PCR*

Approximately 100 mg of frozen liver tissue was homogenized in 1 ml of RNazol RT (#R4533; Sigma-Aldrich),

and mRNA was extracted according to the product technical bulletin. Rehydrated RNA was quantified using a NanoDrop Spectrophotometer (Thermo Scientific), and cDNA was synthesized from 1  $\mu$ g of RNA by the iScript cDNA Synthesis Kit (#170-8891; Bio-Rad) according to the manufacturer's protocol. Quantitative real-time PCR (qPCR) reactions using SYBR Green PCR Supermix (#172-5275; Bio-Rad) were performed using a CFX96 Touch Real-Time PCR Detection System, and results were analyzed with the CFX Manager software (Bio-Rad). All samples were analyzed in duplicate. Oligonucleotide primer sequences are listed in Table 1. The qPCR Ct values were normalized to the ribosomal protein L30 or Sfrs4 and reported as "normalized expression" of the indicated gene. L30 was used because we have found that hepatic L30 mRNA levels remain stable at different developmental times; Sfrs4 was used for tumor studies since it is more stable than L30 in these samples<sup>35</sup>. Data shown as fold change were normalized to L30 or Sfrs4, and then normalized to wild-type or control values calculated using the  $\Delta\Delta$ Ct method<sup>36</sup>.

#### *Immunohistochemistry*

Dissected mouse tissues were embedded in OCT media, snap frozen, and stored at -80°C. Sections (10  $\mu$ m) were cut using a Micron HM505 N cryostat, placed onto glass slides, air dried for 10 min, and then fixed in 4% paraformaldehyde for 10 min. Slides were washed twice in cold 1 $\times$  PBS buffer and then blocked with the appropriate

serum-blocking buffer at room temperature for 1 h. Slides were incubated overnight at 4°C with primary anti-Zhx2 antibody (1:250; #96083; Abcam), washed twice with 1× PBS, and incubated with TRITC-conjugated secondary antibody (1:200; #4010-13; Southern Biotech) for 1.5 h at room temperature. Slides were mounted (Dako mounting media; #2013-05), covered, and imaged with a Nikon Eclipse 80i upright microscope with NiS Elements software.


#### Statistical Analysis

All values within a group were averaged and plotted as mean ± standard deviation; *p* values were calculated between two groups using Student's *t*-test. Developmental gene expression analysis was calculated using two-way analysis of variance (ANOVA) plus Bonferroni post hoc test. Sexually dimorphic gene expression data were analyzed by one-way ANOVA plus Tukey post hoc test. A value of *p* ≤ 0.05 was considered significant. Data were graphed and analyzed using GraphPad Prism 6 software.

## RESULTS

### *Zhx2* Is Absent in Hepatocytes of *Zhx2*<sup>Δhep</sup> Mice

Previous studies to investigate *Zhx2* function in vivo used BALB/cJ mice, which have a natural hypomorphic *Zhx2* mutation that reduces, but does not eliminate, *Zhx2* expression<sup>23,26</sup>. To understand better the role of *Zhx2* in hepatocytes, mice with a floxed *Zhx2* allele were bred with *Alb-Cre* transgenic mice to generate mice that were homozygous for the floxed *Zhx2* allele and *Alb-Cre*<sup>+</sup> (*Zhx2*<sup>Δhep</sup>); floxed homozygous littermates that did not contain the *Alb-Cre* transgene (*Zhx2*<sup>fl</sup>) were used as controls. *Zhx2* mRNA levels in the liver of adult male *Zhx2*<sup>Δhep</sup> mice were ~90% lower than that in age-matched *Zhx2*<sup>fl</sup> control mice (Fig. 1A). To confirm the loss of *Zhx2*, hepatic AFP mRNA levels were also analyzed in *Zhx2*<sup>Δhep</sup> and *Zhx2*<sup>fl</sup> adult mice. Similar to what is seen in BALB/cJ mice, AFP levels are roughly eightfold higher in *Zhx2*<sup>Δhep</sup> mice compared to those in *Zhx2*<sup>fl</sup> controls (Fig. 1B); similar differences were seen in female *Zhx2*<sup>Δhep</sup> and *Zhx2*<sup>fl</sup> mice (data not shown). Immunofluorescence staining with anti-*Zhx2* antibodies demonstrated that *Zhx2* is present



**Figure 1.** *Zhx2* is absent in hepatocytes of *Zhx2*<sup>Δhep</sup> mice. (A, B) Total liver RNA was prepared from adult male *Zhx2*<sup>fl/fl</sup>, *Alb-Cre*<sup>+</sup> (*Zhx2*<sup>Δhep</sup>; *n* = 5) and *Zhx2*<sup>fl/fl</sup>, *Alb-Cre*<sup>-</sup> (*Zhx2*<sup>fl</sup>; *n* = 5) mice. Reverse transcriptase quantitative PCR (RT-qPCR) was used to monitor levels of *Zhx2* (A) and AFP (B), which were normalized to L30 mRNA levels. *Zhx2* and AFP mRNA levels in *Zhx2*<sup>fl</sup> mice were set to 1.0, and fold change in *Zhx2*<sup>Δhep</sup> mice is shown. *Zhx2* levels decrease ninefold, whereas AFP levels increase eightfold in *Zhx2*<sup>Δhep</sup> mice. \**p* < 0.05; \*\*\**p* < 0.001. (C, D) Frozen adult liver sections were incubated with anti-*Zhx2* antibody followed by TRITC-conjugated secondary antibody. Nuclear *Zhx2* staining is evident in control *Zhx2*<sup>fl</sup> liver (C) but absent from hepatocytes in *Zhx2*<sup>Δhep</sup> liver, although *Zhx2* staining is still evident in nonparenchymal cells (D).

in hepatocyte nuclei in control *Zhx2<sup>fl</sup>* mice (Fig. 1C). In contrast, Zhx2 protein is not detectable in hepatocytes in adult *Zhx2<sup>Δhep</sup>* mice, although Zhx2 continues to be found in nonparenchymal cells (Fig. 1D). These data confirm that Zhx2 is absent in adult *Zhx2<sup>Δhep</sup>* hepatocytes. Zhx2 mRNA levels are lower in the livers of whole-body Zhx2 knockout mice than in *Zhx2<sup>Δhep</sup>* livers (data not shown), consistent with Zhx2 expression in nonparenchymal cells. Furthermore, Zhx2 mRNA levels in adult *Zhx2<sup>fl</sup>* adult mice are the same as those in wild-type BL/6 mice, indicating that the intronic *loxP* sites do not alter normal Zhx2 mRNA processing (data not shown).


#### *Cyp2a4* mRNA Levels Are Elevated in Male *Zhx2<sup>Δhep</sup>* Liver

Cyp2a4 is normally expressed at much higher levels in the adult livers of female mice compared to adult male liver. However, Cyp2a4 mRNA levels are substantially increased in BALB/cJ male mice but are still lower than what is seen in female adult liver<sup>21</sup>. To test whether this male-specific increase is due to the Zhx2 mutation, hepatic Cyp2a4 mRNA levels were analyzed in *Zhx2<sup>Δhep</sup>* and *Zhx2<sup>fl</sup>* mice. In 8-week-old control *Zhx2<sup>fl</sup>* mice, Cyp2a4 mRNA levels are ~1,000-fold lower in male liver compared to female liver, as expected (Fig. 2A and Table 2). Cyp2a4 mRNA levels are increased nearly eightfold in age-matched *Zhx2<sup>Δhep</sup>* male mice, but still at levels considerably lower than those in *Zhx2<sup>fl</sup>* female mice, whereas Cyp2a4 levels remain essentially the same in *Zhx2<sup>Δhep</sup>* and *Zhx2<sup>fl</sup>* females (Fig. 2A). These data indicate that Zhx2 contributes

significantly to the low Cyp2a4 mRNA levels in adult male mice. Interestingly, Cyp2a5, which is highly related to Cyp2a4 but shows a much more modest female-biased expression in the liver, exhibits only a 3.1-fold increase in *Zhx2<sup>Δhep</sup>* male mice (Fig. 2B and Table 2).

#### *Zhx2* Regulates Multiple Female-Biased Cyp Gene Expression in Adult Male Mice

A number of Cyp enzymes in addition to Cyp2a4 exhibit sex-biased expression, with some being expressed at higher levels in females and others in males. Since Cyp2a4 mRNA levels increased in male *Zhx2<sup>Δhep</sup>* mice, we evaluated the expression of other hepatic Cyp enzymes in the presence or absence of Zhx2. In addition to Cyp2a4 and Cyp2a5, six Cyp genes previously shown to be expressed at higher levels in female mice, to varying degrees, were examined. In general, the loss of hepatic Zhx2 led to increased expression of these female-biased Cyp genes in adult male liver (Fig. 3A and Table 2). The increase was robust in several cases (over 33-fold for Cyp2b13) and more modest for other enzymes. Expression of these six Cyp genes was generally not affected by the loss of Zhx2 in female *Zhx2<sup>Δhep</sup>* mice, except for a modest decrease in Cyp4a10 and a more robust decrease in Cyp7a1 mRNA levels. Interestingly, Cyp7a1 is the rate-limiting enzyme that converts cholesterol to bile acids, so alterations in its expression likely affects cholesterol metabolism. This increase in female-biased Cyp genes in male livers is similar to what was seen with Cyp2a4. A different pattern was seen with several male-biased Cyp enzymes (Fig. 3B and Table 2).



**Figure 2.** *Cyp2a4* and *Cyp2a5* mRNA levels are elevated in adult liver of male *Zhx2<sup>Δhep</sup>* mice. Total liver RNA was prepared from 8-week-old male and female *Zhx2<sup>Δhep</sup>* and control *Zhx2<sup>fl</sup>* mice. RT-qPCR was used to monitor levels of *Cyp2a4* mRNA (A) and *Cyp2a5* (B), normalized to L30 mRNA levels. *Cyp2a4* levels are eightfold higher in male livers from *Zhx2<sup>Δhep</sup>* mice ( $n=9$ ) compared to *Zhx2<sup>fl</sup>* male mice ( $n=5$ ). Expression of *Cyp2a5*, which is highly related to *Cyp2a4*, shows a modest increase in male *Zhx2<sup>Δhep</sup>* mice that is not significant. *Cyp2a4* and *Cyp2a5* mRNA levels are the same in female *Zhx2<sup>Δhep</sup>* ( $n=8$ ) and *Zhx2<sup>fl</sup>* ( $n=4$ ) mice. \* $p<0.05$ ; \*\*\* $p<0.001$ .

**Table 2.** Sex-Biased *Cyp* Expression in Female and Male *Zhx2<sup>Δhep</sup>* and *Zhx2<sup>fl</sup>* Mouse Liver

	Published Bias	Female/Male Ratio in <i>Zhx2<sup>fl</sup></i> Mice	Male <i>Zhx2<sup>Δhep</sup></i> / <i>Zhx2<sup>fl</sup></i> Ratio	Female <i>Zhx2<sup>Δhep</sup></i> / <i>Zhx2<sup>fl</sup></i> Ratio
Female biased				
Cyp2b13	Female <sup>9</sup>	10,936	33.7	1
Cyp2a4	Female <sup>9</sup>	981	7.9	1
Cyp2b9	Female <sup>9</sup>	770	6.8	1
Cyp4a10	Female <sup>9</sup>	7.1	5.4	0.4
Cyp39a1	Female <sup>8</sup>	1.5	4.8	1.8
Cyp2a5	Female <sup>9</sup>	3.2	3.1	1.1
Cyp2c40	Female <sup>9</sup>	5.8	1.5	1.2
Cyp7a1	n/a	7.0	1.2	0.1
Male biased				
Cyp4a12	Male <sup>9</sup>	0.002	0.9	0.6
Cyp2d9	Male <sup>9</sup>	0.4	0.9	0.9
Cyp8b1	Male <sup>10</sup>	0.6	1.2	0.9
Unbiased				
Cyp3a25	Unbiased <sup>9</sup>	0.6	1	1.1
Cyp2d10	Unbiased <sup>9</sup>	0.6	0.8	0.9
Cyp3a16	Female <sup>9</sup>	0.8	2.1	1

Analysis of liver mRNA expression levels of 14 *Cyp* genes examined (female biased, male biased, and unbiased) is categorized based on sex differences seen in adult *Zhx2<sup>fl</sup>* mice. Ratios are based on data shown in Figures 2 and 3. A previous report indicated Cyp3a16 is a female-specific *Cyp* gene, but this was not seen in our study. n/a, not available.

Two that were analyzed, Cyp8b1 and Cyp2d9, showed little change in either sex in *Zhx2<sup>Δhep</sup>* liver compared to *Zhx2<sup>fl</sup>* liver, whereas a third, Cyp4a12, was only slightly reduced in female *Zhx2<sup>Δhep</sup>* mice. Three *Cyp* enzymes that are expressed at roughly equal levels in both sexes, Cyp3a25, Cyp2d10, and Cyp3a16, show little change in expression in response to the loss of *Zhx2* (Fig. 3C and Table 2).


#### *Cyp2a4*, *Cyp2b13*, and *Cyp4a12* mRNA Levels Are Developmentally Regulated in the Postnatal Liver

Previously identified *Zhx2* targets, including AFP, H19 and *Gpc3*, are expressed abundantly in the fetal liver and silenced after birth but do not exhibit sex-biased expression. This led us to investigate developmental changes in the expression of female-biased *Cyp2a4* and *Cyp2b13* and male-biased *Cyp4a12* in both sexes. Since *Zhx2* is involved in male-specific silencing of female-biased *Cyps*, we also monitored changes in *Zhx2* mRNA levels in male and female mice. At e17.5, *Zhx2* levels are higher in female than in male fetuses (Fig. 4A). *Zhx2* mRNA levels in female mice remain steady through p7, exhibit a slight increase at p14 and another modest increase at p28. In contrast, male liver *Zhx2* mRNA levels exhibit a slow but steady increase between e17.5 and p28, but then show a dramatic ~7-fold increase between p28 and p56 (Fig. 4A). In both sexes, *Cyp2a4* levels are very low in the e17.5 liver and show a gradual increase during the first 3 weeks after birth (Fig. 4B). The sex bias in *Cyp2a4* levels is first evident at p28; *Cyp2a4* levels remain relatively steady in


male mice at this time point but increase over 10-fold in female mice. *Cyp2a4* levels remain high 8 weeks after birth in female livers. However, in male liver, *Cyp2a4* levels exhibit a dramatic reduction after p28, decreasing to barely detectable levels by p56. Thus, the dramatic difference in hepatic *Cyp2a4* mRNA levels between male and female mice is established between p28 and p56, indicating that male-specific *Cyp2a4* silencing is associated with sexual maturity that occurs between 4 and 8 weeks after birth. A somewhat similar pattern is seen with *Cyp2b13*. Expression of *Cyp2b13* increases in both sexes between e17.5 and p7. *Cyp2b13* levels gradually increase between p14 and p56 in females and decrease in male mice during the same period, although the most dramatic change in male mice occurs between p28 and p56 (Fig. 4C). *Zhx2* also shows a significant increase in male mice between p28 and p56, which supports the possibility that *Zhx2* contributes to *Cyp2a4* and *Cyp2b13* silencing in the adult male liver. The developmental changes in male-biased *Cyp4a12* mRNA levels are different than what is seen with female-biased *Cyps* (Fig. 4D). *Cyp4a12* levels are low but found at equal levels in male and female livers at e17.5. Levels in both sexes remain low until p28, at which time *Cyp4a12* mRNA levels increase dramatically in male livers.

#### *Sex-Biased Cyp Enzymes Are Disregulated in a Mouse Model of HCC*

A hallmark of previously identified *Zhx2* targets is that they are frequently reactivated in HCC and other



**Figure 3.** Zhx2 represses female-biased Cyp genes in adult male mice. Liver mRNA was analyzed by RT-qPCR in adult male and female Zhx2<sup>fl</sup> and Zhx2<sup>Δhep</sup> littermates (male: Zhx2<sup>fl</sup> n=5, Zhx2<sup>Δhep</sup> n=9; female Zhx2<sup>fl</sup> n=4, Zhx2<sup>Δhep</sup> n=8). (A) Six Cyp genes characterized as being more abundant in females were analyzed. Four genes, Cyp2b13, Cyp2b9, Cyp4a10 and Cyp39a1, increased significantly in male Zhx2<sup>Δhep</sup> mice; a more modest increase was observed with Cyp2c40 and Cyp7a1, which was the only female-biased Cyp analyzed that decreased in female Zhx2<sup>Δhep</sup> liver. (B) Three Cyp genes typically more abundant in males were analyzed. There is no difference in expression in male Zhx2<sup>Δhep</sup> mice compared to Zhx2<sup>fl</sup> controls. Female Zhx2<sup>Δhep</sup> mice exhibited slightly reduced Cyp4a12 expression. (C) The absence of Zhx2 does not significantly change expression of Cyp genes that are expressed equally in males and females. \*p < 0.05.




**Figure 4.** Developmental changes in *Zhx2*, *Cyp2a4*, *Cyp2b13*, and *Cyp4a12* expression are different in male and female mice. Hepatic *Zhx2* and *Cyp* mRNA levels, at e17.5 and various postnatal time points ( $n=4-10$ /group), were analyzed in male and female B6C3F1 mice by RT-qPCR and normalized to L30. (A) Female *Zhx2* mRNA levels show a modest increase between p7 and p14 and again between p21 and p28. Male *Zhx2* mRNA levels increase gradually between e17.5 and p28 and a more dramatic (~7-fold) increase between p28 and p56. (B) *Cyp2a4* mRNA levels increase between e17.5 and p21 in male and female livers. Between p21 and p28, female hepatic *Cyp2a4* levels increase over 10-fold and remain high at p56. In contrast, male hepatic *Cyp2a4* levels decrease dramatically between 4 and 8 weeks of age to levels that are barely detectable. (C) *Cyp2b13* mRNA levels increase between e17.5 and p7 in male and female livers. Between p14 and p56, female hepatic *Cyp2b13* levels gradually increase; male *Cyp2b13* levels decrease over this same period to levels that are barely detectable by p56. (D) *Cyp4a12* mRNA levels are expressed at low but equal levels in both male and female livers at e17.5. Levels drop in both sexes after birth and remain very low in female liver. In male liver, *Cyp4a12* levels increase over 50-fold between p21 and p28 and remain high at p56. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ .

liver cancers. This led us to ask whether female-biased *Cyp* genes, which are repressed by *Zhx2* in male mice, are also activated in liver tumors. Male B6C3F1 mice were injected with DEN or PBS. After 36 weeks, mice were euthanized and livers were removed. Livers of DEN-injected mice had numerous tumors, whereas the livers of PBS-injected mice were tumor free. RNA was prepared from dissected tumors and the control PBS-injected liver and analyzed by RT-qPCR. *Cyp2a4* levels

were dramatically higher in the tumors compared to the control liver (Fig. 5), indicating that *Cyp2a4* is activated in liver cancer. Expression of *Cyp2b9* and *Cyp2b13* was also increased in liver tumors, whereas the female-biased *Cyp2b5* expression was unchanged in tumors. In contrast to the majority of female-biased *Cyps*, the male-biased *Cyp4a12* gene exhibited a substantial decrease in liver tumor samples compared to normal adult liver (Fig. 5).





**Figure 5.** Cyp mRNA levels are altered in mouse liver tumors. B6C3F1 male mice were injected with PBS ( $n=5$ ) or DEN ( $n=16$ ) at p14 to induce HCC tumor formation. Livers were harvested 36 weeks postinjection. The DEN-injected mice had massive liver tumors, whereas no tumors were present in the PBS-injected livers. Levels of female-biased Cyp2a4, Cyp2b13, and Cyp2b9 increased significantly in tumors (T, gray bars) compared to PBS-injected livers (C, black bars); female-biased Cyp2a5 showed no change in tumors. In contrast, the male-biased Cyp4a12 decreased in tumor samples compared to normal liver. \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ .

## DISCUSSION

Previous studies demonstrated that Zhx2 contributes to the silencing of fetal genes in the postnatal mouse liver<sup>22–24,37</sup>. Here, we provide the first evidence that Zhx2 also contributes to sex-biased gene expression in the adult liver by repressing female-biased *Cyp* genes in the adult male liver, indicating a link between developmental and sex-biased hepatic gene expression. Although Zhx2 contributes to the silencing of female-biased *Cyp* genes in male livers and of fetal-expressed genes, there are fundamental differences in these types of repression. Female-biased *Cyp* genes are derepressed in adult male hepatocytes in the absence of Zhx2, whereas expression of these genes is, in most cases, not altered in female *Zhx2<sup>Δhep</sup>* livers. In contrast, hepatic AFP, H19, and Gpc3 mRNA levels are elevated in both male and female mice when Zhx2 is deleted, indicating that Zhx2 represses these targets in both sexes. Furthermore, the temporal pattern of postnatal changes in sex-biased Cyps and previously identified Zhx2 targets are dramatically different. AFP, H19, and Gpc3 are abundantly expressed in the fetal liver, and mRNA levels of these genes decrease dramatically during the first 4 weeks after birth<sup>22–24,37</sup>. However, female-biased Cyp2a4 and Cyp2b13 are not expressed at e17.5 in the livers of either sex. Expression of both Cyps increases in male and female liver within the first several weeks after birth, but continues to increase in female livers and decrease in male livers. These changes are gradual for Cyp2b13 but more dramatic for Cyp2a4, with hepatic Cyp2a4 mRNA levels exhibiting a significant increase in females between p21 and p28 and a striking reduction in males between p28 and p56, ultimately leading to the ~1,000-fold difference in Cyp2a4 levels seen between 8-week-old male and female

mice. Thus, sex differences in Cyp2a4 and, to a lesser extent with Cyp2b13, do not occur when fetal genes are being repressed but rather when mice are reaching sexual maturity. Variations in the cross talk between Zhx2 and other factors/signaling pathways could possibly account for differences in the silencing of fetal-expressed and sex-biased genes.

Previously identified Zhx2 targets, including AFP, H19, and Gpc3, are frequently activated in HCC in mice and humans<sup>38</sup>. Cyp2a4, Cyp2b13, and Cyp2b9 are also activated in DEN-induced mouse liver tumors, although the female-biased Cyp2a5, which does show a modest increase in Zhx2-deficient male livers, did not increase in tumors. Interestingly, the male-biased *Cyp4a12* gene, which does not appear to be a target of Zhx2, is decreased in liver tumors compared to normal adult liver. Similar changes in these *Cyp* genes in livers tumors were recently reported<sup>39</sup>. CYP2A6, a human CYP expressed in the liver that has the highest sequence homology to mouse Cyp2a4, is frequently upregulated in human HCC samples<sup>40</sup>. Taken together, these data suggest a potential role for Zhx2 in HCC progression via expression of target genes. Consistent with this possibility, nuclear Zhx2 protein levels are reduced in human HCC samples compared to nontumor liver tissue, suggesting that differential Zhx2 localization could account for the lack of repression of Zhx2 targets in HCC<sup>41</sup> (K. T. Creasy and B. T. Spear, unpublished observations). Since HCC is more common in males than in females in both humans and mice<sup>42–44</sup>, it is interesting to consider whether Zhx2, through the control of its targets in a sex-biased manner, may contribute to this difference.

Most female-biased *Cyp* genes we analyzed remain unchanged in *Zhx2<sup>Δhep</sup>* females but are derepressed in the liver of adult male *Zhx2<sup>Δhep</sup>* mice, although Cyp mRNA levels are still considerably lower than what is found in wild-type adult female liver. In general, male-biased and unbiased *Cyp* genes do not respond to changes in Zhx2. Cyp2a5, which is highly related to Cyp2a4, shows a less pronounced female-biased expression and is less responsive to changes in Zhx2 expression. Interestingly, *Cyp* genes that exhibit the strongest female bias also have the greatest increase in *Zhx2<sup>Δhep</sup>* male mice. This is most evident with Cyp2b13, which exhibits a ~10<sup>4</sup> female bias in *Zhx2<sup>fl</sup>* mice and increases over 30-fold in male livers in the absence of Zhx2 (Table 2). The three Cyps that show the greatest change in the absence of Zhx2 in male liver, Cyp2b13, Cyp2a4, and Cyp2b9, are tightly clustered on mouse chromosome 7; whether this indicates coordinated regulation will require further investigation. Consistent with our studies in knockout mice, these three Cyps were also found to be increased in BALB/cJ adult male liver<sup>28</sup>.

Sex-biased *Cyp* gene expression is attributed to STAT5 activation via GH signaling<sup>15,45</sup>. STAT5b is necessary for expression of male-specific *Cyp* genes, whereas both

STAT5a and STAT5b are required for female *Cyp* gene patterning<sup>16</sup>. GH is secreted in a pulsating manner in males, while females have more steady GH circulation<sup>17</sup>. HNF4 $\alpha$ , a key regulator of numerous hepatic genes, is necessary for the normal expression of multiple sex-biased *Cyp* genes in the liver<sup>46,47</sup>. A current model that integrates HNF4 $\alpha$  with GH signaling suggests the pulsating spike in GH in male mice activates STAT5b, and possibly HNF4 $\alpha$ , increasing transcription of male-specific *Cyp* genes. The continuous GH levels in females fail to fully activate STAT5b and therefore may not be sufficient to activate male *Cyp* genes; increased HNF6 and Foxa2 activity in females due to continuous GH signaling may contribute to female-biased *Cyp* expression<sup>47,48</sup>. *Cux2* activates female-biased *Cyp* genes in female liver, whereas *Bcl6* represses these genes in male liver<sup>18,19</sup>. Our studies indicate that *Zhx2* contributes, in part, to the active repression of female-biased *Cyp* genes in the male liver. Whether this is due to interactions between *Zhx2* and *Bcl6* or other factors involved in GH/Stat5b signaling will require further studies. We have found that *Stat5b*, *Cux2*, *Bcl6*, *Stat5a*, and *Stat5b* mRNA levels are not altered in male or female adult liver of *Zhx2*<sup>*Δhep*</sup> mice (unpublished data), so regulation of these genes by *Zhx2* cannot account *Zhx2* repression of female-biased genes in male mice.

In conclusion, our studies expand considerably the number of hepatic genes controlled by *Zhx2* and indicate that *Zhx2* represses female-biased genes in adult male livers. Other studies indicate that lipoprotein lipase (*Lpl*), elongation of very long chain fatty acids-like 3 (*Elovl3*), and murine major urinary protein (*Mup*) genes are also targets of *Zhx2* and misregulated in HCC (manuscript in preparation). This expanding number of *Zhx2* targets, along with liver functions associated with these targets, provides further evidence that *Zhx2* is an important regulator of hepatic gene expression in normal and diseased liver. *Zhx2* is also expressed in other tissues, and at least some *Zhx2* targets are also misregulated in whole-body *Zhx2* knockout mice (unpublished observations), suggesting that *Zhx2* has a role in controlling gene expression in multiple tissues. The floxed *Zhx2* mice described here will be essential to fully understand the role of *Zhx2* in health and disease.

**ACKNOWLEDGMENTS:** *This work is supported by Public Health Service Grants R01DK074816 (B.T.S.), P20RR021954 (B.T.S.), and T32DK007778 (K.T.C.); National Science Foundation grant MCB-1158234 (M.L.P.); and American Heart Association 10PRE4250000 (H.R.).*

## REFERENCES

- Nelson DR, Goldstone JV, Stegeman JJ. The cytochrome P450 genesis locus: The origin and evolution of animal cytochrome P450s. *Philos Trans R Soc Lond B Biol Sci.* 2013;368:20120474.
- Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW and others. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. *Pharmacogenetics* 1996;6:1–42.
- Nebert DW, Russell DW. Clinical importance of the cytochromes P450. *Lancet* 2002;360:1155–62.
- Nebert DW, Wikvall K, Miller WL. Human cytochromes P450 in health and disease. *Philos Trans R Soc Lond B Biol Sci.* 2013;368:20120431.
- Choudhury AI, Chahal S, Bell AR, Tomlinson SR, Roberts RA, Salter AM, Bell DR. Species differences in peroxisome proliferation; mechanisms and relevance. *Mutat Res.* 2000;448:201–12.
- Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. *Proc Natl Acad Sci USA* 1993;90:11825–9.
- Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. *Pharmacogenetics* 2004;14:1–18.
- Li-Hawkins J, Lund EG, Bronson AD, Russell DW. Expression cloning of an oxysterol 7 $\alpha$ -hydroxylase selective for 24-hydroxycholesterol. *J Biol Chem.* 2000; 275:16543–9.
- Renaud HJ, Cui JY, Khan M, Klaassen CD. Tissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in mice. *Toxicol Sci.* 2011;124:261–77.
- Zhang M, Chiang JY. Transcriptional regulation of the human sterol 12 $\alpha$ -hydroxylase gene (CYP8B1): Roles of hepatocyte nuclear factor 4 $\alpha$  in mediating bile acid repression. *J Biol Chem.* 2001;276:41690–9.
- Graham MJ, Lake BG. Induction of drug metabolism: Species differences and toxicological relevance. *Toxicology* 2008;254:184–91.
- Dvorak Z, Pavek P. Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. *Drug Metab Rev.* 2010;42:621–35.
- Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. *Mol Pharmacol.* 2009;76:215–28.
- Waxman DJ. Regulation of liver-specific steroid metabolizing cytochromes P450: Cholesterol 7 $\alpha$ -hydroxylase, bile acid 6 $\beta$ -hydroxylase, and growth hormone-responsive steroid hormone hydroxylases. *J Steroid Biochem Mol Biol.* 1992;43:1055–72.
- Davey HW, Wilkins RJ, Waxman DJ. STAT5 signaling in sexually dimorphic gene expression and growth patterns. *Am J Hum Genet.* 1999;65:959–65.
- Park SH, Liu X, Hennighausen L, Davey HW, Waxman DJ. Distinctive roles of STAT5a and STAT5b in sexual dimorphism of hepatic P450 gene expression. Impact of STAT5a gene disruption. *J Biol Chem.* 1999;274:7421–30.
- Waxman DJ, Ram PA, Park SH, Choi HK. Intermittent plasma growth hormone triggers tyrosine phosphorylation and nuclear translocation of a liver-expressed, Stat 5-related DNA binding protein. Proposed role as an intracellular regulator of male-specific liver gene transcription. *J Biol Chem.* 1995;270:13262–70.
- Conforto TL, Zhang Y, Sherman J, Waxman DJ. Impact of CUX2 on the female mouse liver transcriptome: Activation

- of female-biased genes and repression of male-biased genes. *Mol Cell Biol.* 2012;32:4611–27.
19. Meyer RD, Laz EV, Su T, Waxman DJ. Male-specific hepatic Bcl6: Growth hormone-induced block of transcription elongation in females and binding to target genes inversely coordinated with STAT5. *Mol Endocrinol.* 2009; 23:1914–26.
  20. Hernandez JP, Chapman LM, Kretschmer XC, Baldwin WS. Gender-specific induction of cytochrome P450s in non-lyphenol-treated FVB/NJ mice. *Toxicol Appl Pharmacol.* 2006;216:186–96.
  21. Aida K, Negishi M. A trans-acting locus regulates transcriptional repression of the female-specific steroid 15 alpha-hydroxylase gene in male mice. *J Mol Endocrinol.* 1993;11:213–22.
  22. Morford LA, Davis C, Jin L, Dobierzewska A, Peterson ML, Spear BT. The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2. *Hepatology* 2007;46:1541–7.
  23. Perincheri S, Dingle RW, Peterson ML, Spear BT. Hereditary persistence of alpha-fetoprotein and H19 expression in liver of BALB/cJ mice is due to a retrovirus insertion in the *Zhx2* gene. *Proc Natl Acad Sci USA* 2005;102:396–401.
  24. Tilghman SM, Belayew A. Transcriptional control of the murine albumin:  $\alpha$ -Fetoprotein locus during development. *Proc Natl Acad Sci USA* 1982;79:5254–7.
  25. Blankenhorn EP, Duncan R, Huppi C, Potter M. Chromosomal location of the regulator of mouse  $\alpha$ -fetoprotein, *afr-1*. *Genetics* 1988;119:687–91.
  26. Perincheri S, Peyton DK, Glenn M, Peterson ML, Spear BT. Characterization of the ETnII-alpha endogenous retroviral element in the BALB/cJ *Zhx2* (*Afr1*) allele. *Mamm Genome* 2008;19:26–31.
  27. Wang X, Gargalovic P, Wong J, Gu JL, Wu X, Qi H, Wen P, Xi L, Tan B, Gogliotti R, Castellani LW, Chatterjee A, Lusis AJ. *Hyplip2*, a new gene for combined hyperlipidemia and increased atherosclerosis. *Arterioscler. Thromb Vasc Biol.* 2004;24:1928–34.
  28. Gargalovic PS, Erbilgin A, Kohannim O, Pagnon J, Wang X, Castellani L, Leboeuf R, Peterson ML, Spear BT, Lusis AJ. Quantitative trait locus mapping and identification of *zhx2* as a novel regulator of plasma lipid metabolism. *Circ Cardiovasc Genet.* 2010;3:60–7.
  29. Kawata H, Yamada K, Shou Z, Mizutani T, Yazawa T, Yoshino M, Sekiguchi T, Kajitani T, Miyamoto K. Zinc-fingers and homeoboxes (*ZHX*) 2, a novel member of the *ZHX* family, functions as a transcriptional repressor. *Biochem J.* 2003;373:747–57.
  30. Kawata H, Yamada D, Shou Z, Mizutani T, Miyamoto K. The mouse zinc-fingers and homeoboxes (*ZHX*) family; *ZHX2* forms a heterodimer with *ZHX3*. *Gene* 2003;323: 133–40.
  31. Yamada K, Kawata H, Shou Z, Hirano S, Mizutani T, Yazawa T, Sekiguchi T, Yoshino M, Kajitani T, Miyamoto K. Analysis of zinc-fingers and homeoboxes (*ZHX*)-1-interacting proteins: Molecular cloning and characterization of a member of the *ZHX* family, *ZHX3*. *Biochem J.* 2003;373:167–78.
  32. Peyton DK, Huang M-C, Giglia MA, Hughes NK, Spear BT. The alpha-fetoprotein promoter is the target of *Afr1*-mediated postnatal repression. *Genomics* 2000;63:173–80.
  33. Karin M. Nuclear factor-kappaB in cancer development and progression. *Nature* 2006;441:431–6.
  34. Drinkwater NR, Hanigan MH, Kemp CJ. Genetic determinants of hepatocarcinogenesis in the B6C3F1 mouse. *Toxicol Lett.* 1989;49:255–65.
  35. Waxman S, Wurbach E. De-regulation of common house-keeping genes in hepatocellular carcinoma. *BMC Genomics* 2007;8:243.
  36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001;25:402–8.
  37. Pachnis V, Belayew A, Tilghman SM. Locus unlinked to  $\alpha$ -fetoprotein under the control of the murine *raf* and *Rif* genes. *Proc Natl Acad Sci USA* 1984;81:5523–7.
  38. Peterson ML, Ma C, Spear BT. *Zhx2* and *Zbtb20*: Novel regulators of postnatal alpha-fetoprotein repression and their potential role in gene reactivation during liver cancer. *Semin Cancer Biol.* 2011;21:21–7.
  39. He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y, Shalpour S, Seki E, Yost SE, Jepsen K and others. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. *Cell* 2013;155:384–96.
  40. Raunio H, Juvonen R, Pasanen M, Pelkonen O, Paakko P, Soini Y. Cytochrome P450A6 (*CYP2A6*) expression in human hepatocellular carcinoma. *Hepatology* 1998;27: 427–32.
  41. Yue X, Zhang Z, Liang X, Gao L, Zhang X, Zhao D, Liu X, Ma H, Guo M, Spear BT, Gong Y, Ma, C. Zinc fingers and homeoboxes 2 inhibits hepatocellular carcinoma cell proliferation and represses expression of cyclins A and E. *Gastroenterology* 2012;142:1559–70 e2.
  42. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: Worldwide incidence and trends. *Gastroenterology* 2004;127:S5–16.
  43. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. *Gastroenterology* 2007;132:2557–76.
  44. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in *MyD88*-dependent IL-6 production. *Science* 2007;317:121–4.
  45. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, Waxman DJ, Davey HW. Requirement of *STAT5b* for sexual dimorphism of body growth rates and liver gene expression. *Proc Natl Acad Sci USA* 1997;94: 7239–44.
  46. Chandra V, Huang P, Potluri N, Wu D, Kim Y, Rastinejad F. Multidomain integration in the structure of the HNF-4alpha nuclear receptor complex. *Nature* 2013;495:394–8.
  47. Wiwi CA, Waxman DJ. Role of hepatocyte nuclear factors in growth hormone-regulated, sexually dimorphic expression of liver cytochromes P450. *Growth Factors* 2004;22:79–88.
  48. Holloway MG, Miles GD, Dombkowski AA, Waxman DJ. Liver-specific hepatocyte nuclear factor-4alpha deficiency: Greater impact on gene expression in male than in female mouse liver. *Mol Endocrinol.* 2008;22:1274–86.